U084 - Isotretinoin Update
Monday, March 4; 7:30 AM - 8:30 AM
Following this course, the attendee should be able to:
- Discuss the current literature regarding risks and benefits of istoretinoin for acne.
- Compare the pros and cons of prescribing isotretinoin for acne.
Isotretinoin is a very effective treatment for acne but its potential risks has limited its use. Is this based on evidence or on fear? We will examine the proper use of isotretinoin, appropriate dosing, and expectations of treatment. The most recent evidence regarding risks of isotretinoin will be reviewed. Based on our current knowledge, we will consider whether or not we should be prescribing isotretinoin to more of our acne patients.
- Harper, Julie Claire, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – SP(H); Aqua – C(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Sun Pharmaceutical Industries Ltd. – C(Fees); Taro Pharm – A(H); Valeant Pharmaceuticals North America LLC – SP(H);
Dr. Harper / Isotretinoin Update